Health and Fitness

Risk for Guillain-Barré Syndrome Up After Ad.26.COV2.S Vaccination – Consumer Health News

TUESDAY, April 26, 2022 (HealthDay News) — The incidence of Guillain-Barré syndrome (GBS) is elevated after Ad.26.COV2.S vaccination, however incidence shouldn’t be elevated after mRNA vaccination, in accordance with a research printed on-line April 26 in JAMA Network Open.

Kayla E. Hanson, M.P.H., from the Marshfield Clinic Research Institute in Wisconsin, and colleagues used information from the Vaccine Safety Datalink to explain the incidence of GBS following COVID-19 vaccination. Data have been included for 10,158,003 individuals who have been aged 12 years or older.

From Dec. 13, 2020, via Nov. 13, 2021, 15,120,073 doses of COVID-19 vaccine have been administered to 7,894,989 people, together with 483,053 Ad.26.COV2.S doses, 8,806,595 BNT162b2 doses, and 5,830,425 mRNA-1273 doses. The researchers confirmed 11 circumstances of GBS after Ad.26.COV2.S vaccination. The unadjusted incidence price of GBS was 32.4 per 100,000 person-years within the one to 21 days after Ad.26.COV2.S, which was considerably larger than the background price; the adjusted price ratio was 6.03 within the one to 21 versus 22 to 42 days following Ad.26.COV2.S vaccination. There have been 36 confirmed circumstances of GBS after mRNA vaccines, for an unadjusted incidence price of 1.3 per 100,000 within the one to 21 days after vaccination. The adjusted price ratio was 0.56 within the one to 21 versus 22 to 42 days after vaccination. The adjusted price ratio was 20.56 in a head-to-head comparability of Ad.26.COV2.S versus mRNA vaccines.

“In this interim analysis of surveillance data of COVID-19 vaccines, findings were consistent with an elevated risk of GBS after primary Ad.26.COV2.S vaccination,” the authors write.

Several authors disclosed monetary ties to the pharmaceutical business, together with receipt of grants from producers of COVID-19 vaccines; one writer disclosed ties to Arnold Ventures.

Abstract/Full Text

Source hyperlink

Leave a Reply

Your email address will not be published.